Describe the threshold effect of localized IL-12 overexpression in driving anti-cancer immunotherapy.

Delineate the mechanisms of localized IL-12 effects in antigen-independent immunotherapy.

Outline a novel clinical gene therapy trial that has been approved for this approach in treating AML and is actively recruiting patients.

Define the different mechanisms that contribute to tumor heterogeneity

Understand how the microenvironment interacts with tumor cells to contribute to cell plasticity

Understand how cell plasticity functions as a major mediator of Ewing sarcoma metastasis

Discuss the potential therapeutic implications of this for cancer therapy

Understand basic principles of B cell selection and cellular origins of childhood ALL

Compare the paradigm of targeted therapy in cancer (e.g. tyrosine kinase inhibitors) with targeted hyperactivation of signaling (tolerance checkpoints).

Discuss how pharmacological hyperactivation of oncogenic signaling triggers deletional checkpoints for elimination of autoreactive B cells

Review the current clinical and biological biomarkers that are utilized to risk classify neuroblastoma patients and stratify treatment.

Describe the germline genomic variants that contribute to the phenotype of neuroblastoma tumors 3. To discuss the observed racial and ethnic disparities in survival in neuroblastoma and the factors that contribute to these disparities.